DelveInsight’s, “Acetyl-CoA Carboxylase Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Acetyl-CoA Carboxylase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Acetyl-CoA Carboxylase Inhibitors: Overview
Acetyl-CoA carboxylase (ACC) is a biotin-dependent enzyme that catalyzes the irreversible carboxylation of acetyl-CoA to produce malonyl-CoA through its two catalytic activities, biotin carboxylase (BC) and carboxyltransferase (CT). ACC is a multi-subunit enzyme in most prokaryotes and in the chloroplasts of most plants and algae, whereas it is a large, multi-domain enzyme in the cytoplasm of most eukaryotes. The most important function of ACC is to provide the malonyl-CoA substrate for the biosynthesis of fatty acids.
Function - Acetyl-CoA carboxylase catalyzes the carboxylation of acetyl-CoA to malonyl-CoA. Hydrolysis of ATP provides the energy to drive this essentially irreversible reaction. Acetyl-CoA carboxylase is considered the key regulatory enzyme in the conversion of citrate to long-chain fatty acids because (i) the concentrations of its substrates and products are far from thermodynamic equilibrium; (ii) the maximum velocity of the enzyme, as measured in cell extracts under optimal conditions, is usually the slowest of all enzymes in the pathway; (iii) the concentration of the product of the enzyme, malonyl-CoA, increases when flux through the pathway increases.
Acetyl-CoA Carboxylase Inhibitors - With the accumulation of information on the ACC functions and structures in the last decade, a variety of ACC inhibitors have been identified, some of which have been approved for clinical trials.
The companies and academics are working to assess challenges and seek opportunities that could influence Acetyl-CoA Carboxylase Inhibitors R&D. The therapies under development are focused on novel approaches for Acetyl-CoA Carboxylase Inhibitors.
This segment of the Acetyl-CoA Carboxylase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acetyl-CoA Carboxylase Inhibitors Emerging Drugs
Firsocostat: Gilead Sciences
Firsocostat is being developed by Gilead Sciences for the treatment of Non-alcoholic fatty liver disease and Non-alcoholic steatohepatitis. The drug is currently in phase 2 of clinical trials.
Clesacostat: Pfizer
Clesacostat is an Acetyl-CoA carboxylase inhibitor developed by Pfizer for the treatment of Non-alcoholic fatty liver disease and Non-alcoholic steatohepatitis. The drug is currently in phase 2 of clinical trials.
Further product details are provided in the report……..
This segment of the report provides insights about the different Acetyl-CoA Carboxylase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 3+ key companies which are developing the Acetyl-CoA Carboxylase Inhibitors. The companies which have their Acetyl-CoA Carboxylase Inhibitors drug candidates in the most advanced stage, i.e. phase II include, Gilead Sciences.
DelveInsight’s report covers around 3+ products under different phases of clinical development like
Acetyl-CoA Carboxylase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acetyl-CoA Carboxylase Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acetyl-CoA Carboxylase Inhibitors drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Acetyl-CoA Carboxylase Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
Acetyl-CoA Carboxylase Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Acetyl-CoA Carboxylase Inhibitors Collaboration Deals
Late Stage Products (Pre-registration)
Drug name: Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Firsocostat: Gilead Sciences
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug name: Company name
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
AK 1225: Akanocure Pharmaceuticals
Drug profiles in the detailed report…..
Inactive Products
Acetyl-CoA Carboxylase Inhibitors Key Companies
Acetyl-CoA Carboxylase Inhibitors Key Products
Acetyl-CoA Carboxylase Inhibitors- Unmet Needs
Acetyl-CoA Carboxylase Inhibitors- Market Drivers and Barriers
Acetyl-CoA Carboxylase Inhibitors- Future Perspectives and Conclusion
Acetyl-CoA Carboxylase Inhibitors Analyst Views
Acetyl-CoA Carboxylase Inhibitors Key Companies
Appendix
List of Table
Table 1: Total Products for Acetyl-CoA Carboxylase Inhibitors
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Acetyl-CoA Carboxylase Inhibitors
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Gilead Sciences
• Pfizer
• Akanocure Pharmaceuticals
• Novo Nordisk
